Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
Phase 1
Completed
- Conditions
- Overweight and Obesity
- Interventions
- Drug: GMA106 InjectionDrug: GMA106 Matching Placebo
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Gmax Biopharm Australia Pty Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT05054530
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers
Phase 1
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: GMA301 InjectionOther: GMA301 Placebo Injection
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Gmax Biopharm Australia Pty Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04505137
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath